Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report.

摘要: Purpose HER2 mutations are identified in approximately 2% of non-small-cell lung cancer (NSCLC) cases; however, until now, there no approved standard targeted therapy for NSCLC patients harboring mutations. Case presentation We present a 63-year-old male with long smoking history, who was diagnosed stage IV squamous cell cancer. After the failures two lines treatment carboplatin plus gemcitabine and nidaplatin docetaxel, turn, patient received next-generation sequencing circulating tumor DNA to seek potential opportunities. A R896G mutation an allelic fraction 50.77%. The afatinib 40 mg day reached partial response after months treatment. progression-free survival more than 14 ongoing. During treatment, treatment-related paronychia stomatitis occurred relieved without any management. Conclusion This is first case report describing rare responds afatinib. suggests that might be efficacious mutations, these results need further studied prospective clinical trials.